METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets liver fat in MASH patients
Disease control Recruiting nowThis early-stage study tests whether the drug miricorilant can lower the amount of fat the liver produces in people with MASH, a serious fatty liver condition. Eight adults with MASH will take the drug for 6 weeks, and researchers will measure changes in liver fat production and …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New drug shows promise for fatty liver disease in Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called UBT251 for people with MASH, a serious liver condition. The goal is to see if the drug can improve liver health without making scarring worse. About 156 adults with moderate to advanced liver scarring will receive either UBT251 or a pl…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
Weekly injection could reverse liver scarring in NASH patients
Disease control Recruiting nowThis study tests a medicine called survodutide, given as a weekly injection, in 1800 adults with NASH/MASH and moderate to advanced liver fibrosis. The goal is to see if it can improve or reverse liver damage and prevent progression to cirrhosis. Participants receive either survo…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New pill could shrink fatty liver and help weight loss
Disease control Recruiting nowThis study tests an experimental drug called CS060380 in adults with both fatty liver disease (MASH) and obesity. About 120 participants will receive either the drug or a placebo, plus a weight-loss medication, for 36 weeks. The goal is to see if the drug reduces liver fat and bo…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug aims to reverse fatty liver damage in phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called IBI362 in 165 adults with MASH, a serious fatty liver disease with liver scarring. Participants will receive either a low dose, high dose, or placebo for 60 weeks. The main goal is to see if the drug can resolve MASH without worsening …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Gene silencer aims to halt liver scarring in MASH patients
Disease control Recruiting nowThis study tests an experimental drug called ALN-HSD for people with MASH, a liver disease caused by fat buildup that leads to scarring and possible liver failure. The drug uses gene silencing to target the root cause and reduce liver fibrosis. About 120 adults with genetic risk …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
What do MASH patients really think? new study asks before and after care
Knowledge-focused Recruiting nowThis study aims to understand the expectations, attitudes, and needs of 25 adults with MASH (a liver condition linked to metabolism) before and after they join a special care program. Participants will have two interviews to share their experiences. The goal is to improve how doc…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Knowledge-focused
Last updated May 26, 2026 03:13 UTC